Pharsight

Orenitram generic

Orenitram is an anti-hypertension drug, owned by United Therap. It contains the active ingredient treprostinil diolamine and was first authorized for market use on 20 December, 2013.

When will Orenitram generic be available?

The last patent of Orenitram will expire on 11 August, 2031, which indicates the earliest potential date for the availability of Orenitram generics. However, this could be subject to change due to various circumstances such as patent extensions or early patent challenges.

Orenitram uses

Orenitram is primarily used for the treatment of pulmonary arterial hypertension (PAH). treprostinil diolamine - the drug's active ingredient - contributes to its effectiveness. The drug works by dilating the blood vessels in the lungs, which reduces the workload on the heart and improves symptoms of PAH.

Orenitram patent expiration

Orenitram holds a total of 14 patent protections. The drug's patents protect various aspects from its uses to the methods for delivery. The last patent is set to expire on 11 August, 2031 which is notably associated with the Osmotic drug delivery system. Find more details about Orenitram generic and its patent status below.

EPO Oppostions filed on Orenitram

Litigations filed on Orenitram

Orenitram dosage

Want to ask something?